Replies to post #175755 on Biotech Values

[DewDiligence]

(AGEN)—GSK’s MAGE-A3 Cancer Immunotherapeutic Phase-3 Study in NSCLC First Co-Primary Endpoints

http://finance.yahoo.com/news/gsk-mage-a3-cancer-immunotherapeutic-070100644.html

Agenus Inc. (AGEN) today announced that GlaxoSmithKline’s MAGRITi study, a Phase 3 randomized, blinded, placebo-controlled MAGE-A3ii cancer immunotherapeutic trial in non-small cell lung cancer patients, which contains Agenus’QS-21 Stimulon adjuvant, did not meet its first or second co-primary endpoint. The study did not significantly extend the disease-free survival (DFS) period when compared to placebo in the overall MAGE-A3 positive patients or patients who did not receive chemotherapy.

GSK announced that it will continue the study until an analysis of the third co-primary endpoint is complete. The third co-primary endpoint is…[an] analysis is based on gene signature and designed to prospectively identify MAGE-A3 positive patients who may benefit more from treatment. If further analysis shows that the predefined gene signature subset data are successful, there is the potential for regulatory filing. GSK anticipates that these data should be available in 2015.

Don’t hold your breath for the third co-primary endpoint, LOL.